In this article, we will discuss the 12 Best Low Priced Growth Stocks to Invest In Now.

On May 13, Sébastien Page, T. Rowe Price Head of Global Multi-Asset & CIO, joined CNBC’s ‘Squawk Box’ to discuss navigating a stock market hitting consecutive record highs. Addressing whether the market has overextended itself, Page stated that he does not believe that the market is out over its skis. He explained that historically, record highs do not serve as sell signals and do not result in lower returns compared to any other time. He acknowledged that while valuations are high, corporate earnings have been awesome. He pointed out that at the end of March, year-over-year earnings growth for the S&P 500 was projected at 13%, but it is currently running at 27%. In response to this environment, T. Rowe Price is maintaining a neutral stance between stocks and bonds, taking some profits on the broadening trade, and actively hedging against inflation risk. Sharing the colloquial investment advice he gives to his dentist, Page emphasized his current strategy: stay invested, stay diversified, and hedge inflation risk.

To express their investment ideas, Page revealed that T. Rowe Price is moving money out of non-US stocks and into US large-cap stocks, specifically within the growth sector. He highlighted that the valuation for US large-cap growth stocks is currently below its historical five-year average, and the valuation for the Mag 7 is well below its peak. For Page’s firm, buying these large-cap growth equities represents the best way to express the AI trade among various options, supported by phenomenal earnings. He pointed out that the forecasted earnings for US large-cap growth stocks over the next 12 months are at the highest level seen in the 25 years of data he possesses. While acknowledging this sets a high bar, Page noted that large-cap growth stocks consistently beat these high expectations.

Our Methodology

We used screeners to identify stocks that have a track record of delivering earnings growth and have grown their EPS by at least 30% over the past 3 years. We then picked stocks that are trading below $50 per share, and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q4 2025.

Note: All data was sourced on May 18. 

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

12 Best Low Priced Growth Stocks to Invest In Now

12. Super Micro Computer Inc. (NASDAQ:SMCI)

Number of Hedge Fund Holders: 39

Super Micro Computer Inc. (NASDAQ:SMCI) is one of the best low priced growth stocks to invest in now. On May 14, Supermicro appointed Matthew Thauberger as its new Chief Revenue Officer. In this role, Thauberger will lead the company’s global revenue organization, overseeing direct, channel, hyperscale, and strategic sales for its AI and infrastructure solutions. He succeeds Don Clegg, the Senior Vice President of Worldwide Sales, who is retiring from the company.

Thauberger brings over 20 years of global experience in international sales, strategic partnerships, and market expansion within AI computing organizations. Since joining Supermicro in April 2020 as Senior Vice President of Strategy and Business Development, he has managed product launches, expanded the Fortune 500 customer pipeline, and supported growth in the CSP and enterprise storage markets. His prior career includes executive sales leadership roles at Burlywood, Inc., Inspur Systems, and AMAX.

Founder, President, and CEO Charles Liang expressed confidence that Thauberger will help accelerate revenue growth and capture demand in the AI and IT infrastructure sectors. Thauberger noted he looks forward to driving sales across the company’s product portfolio as Super Micro Computer Inc. (NASDAQ:SMCI) enters its next stage of growth.

Super Micro Computer Inc. (NASDAQ:SMCI) sells and develops server and storage solutions based on modular and open-standard architecture across Europe, the US, Asia, and internationally.

11. Exelixis Inc. (NASDAQ:EXEL)

Number of Hedge Fund Holders: 42

Exelixis Inc. (NASDAQ:EXEL) is one of the best low priced growth stocks to invest in now. On May 5, Exelixis reported total revenues of $610.8 million for Q1 2026, up from $555.4 million in Q1 2025. This increase was driven primarily by US net product revenues of $555 million from its cabozantinib franchise, alongside a rise in collaboration revenues to $55.8 million. The company achieved a GAAP net income of $210.5 million ($0.79 diluted EPS) and a non-GAAP net income of $232.8 million ($0.87 diluted EPS), while maintaining its full-year 2026 financial guidance.

On the clinical and regulatory front, the US FDA accepted Exelixis’ first NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, setting a target action date of December 3. The company expanded its GI sales team to support this pipeline and continued progressing across multiple zanzalintinib clinical trials. These include upcoming data readouts for the STELLAR-303 and STELLAR-304 studies, active enrollment in STELLAR-311, and the recent initiation of the phase 2 STELLAR-201 trial for recurrent meningioma.

Financially, Exelixis Inc. (NASDAQ:EXEL) expects to finish its existing $750 million stock repurchase program this month, having bought back $590.6 million in shares as of the end of Q1. Additionally, the Board of Directors authorized a new stock repurchase program in May to buy back up to an extra $750 million of common stock by the end of 2027. This newly approved initiative represents the sixth share repurchase program launched by the company since March 2023.

Exelixis Inc. (NASDAQ:EXEL) is an oncology-focused biopharmaceutical company based in Alameda. It develops small-molecule cancer therapies, led by CABOMETYX (cabozantinib), its main revenue driver. It is also advancing next-gen drugs like zanzalintinib and expanding into new cancer treatment areas.